HYRIMOZ

ADALIMUMAB-ADAZ

Manufacturer: Sandoz Inc

Score: 148.0

Quick Summary

HYRIMOZ (adalimumab-adaz) is a tumor necrosis factor (TNF) blocker used to treat various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered via subcutaneous injection, and dosing varies by condition and patient population. The drug carries warnings for serious infections, malignancies, and other adverse reactions, and has specific considerations for use in pregnancy, nursing mothers, pediatric patients, and geriatric patients.

Key Clinical Findings and Indications

Rheumatoid arthritis
Juvenile idiopathic arthritis
Psoriatic arthritis
Ankylosing spondylitis
Crohn's disease
Ulcerative colitis
Plaque psoriasis
Hidradenitis suppurativa
Uveitis

Important Safety Information

Warning

Increased risk of serious infections and malignancies

Contraindications

Adverse Reactions

Serious infections
Malignancies
Hypersensitivity reactions
Hepatitis B virus reactivation
Neurologic reactions
Hematological reactions
Heart failure
Autoimmunity

Dosing Recommendations

General Guidance

Dose adjustments may be necessary in patients with renal or hepatic impairment

Rheumatoid arthritis

Adult Dose

40 mg every other week

Pediatric Dose

10 mg every other week for patients 10-15 kg, 20 mg every other week for patients 15-30 kg, and 40 mg every other week for patients >30 kg

Crohn's disease

Adult Dose

160 mg on Day 1, 80 mg on Day 15, and 40 mg every other week starting on Day 29

Pediatric Dose

80 mg on Day 1 and 40 mg on Day 15 for patients 17-40 kg, and 160 mg on Day 1 and 80 mg on Day 15 for patients >40 kg

Special Population Considerations

Pregnancy

Use during pregnancy only if potential benefits justify potential risks
Limited data available on use during pregnancy

Nursing Mothers

Limited data available on use during breastfeeding
Caution advised when administering live or live-attenuated vaccines to infants exposed to HYRIMOZ in utero

Pediatric Use

Approved for use in pediatric patients 2 years of age and older with polyarticular juvenile idiopathic arthritis
Approved for use in pediatric patients 6 years of age and older with Crohn's disease

Geriatric Use

No overall difference in effectiveness observed between patients 65 years of age and older and younger patients
Higher frequency of serious infections and malignancies observed in patients 65 years of age and older

Similar Drugs

AMJEVITA

ADALIMUMAB-ATTO

Optum Health Solutions (Ireland) Limited

Similarity: 64.9%

YUSIMRY

ADALIMUMAB-AQVH

Meitheal Pharmaceuticals Inc.

Similarity: 60.7%

Idacio

ADALIMUMAB

Fresenius Kabi USA, LLC

Similarity: 60.7%